Holen Sie sich die Stockscreener-App
27.83
1.73%
-0.49
Handel nachbörslich:
27.82
-0.010
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$28.32
Offen:
$28.19
24-Stunden-Volumen:
25.11M
Relative Volume:
0.56
Marktkapitalisierung:
$158.31B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
20.54
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
+0.22%
1M Leistung:
+2.88%
6M Leistung:
+5.30%
1J Leistung:
+21.16%
1-Tages-Spanne:
$27.81
$28.23
1-Wochen-Bereich:
$27.79
$28.75
52-Wochen-Spanne:
$20.91
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.83 | 161.09B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
Pfizer : Science Will Win season finale explores AI in cancer care with Pfizer Chief Oncology Officer Jeff Legos - marketscreener.com
How AI Is Already Reshaping Cancer Care - Pfizer
Pfizer Inc. $PFE Shares Sold by Quilter Plc - MarketBeat
Pfizer Inc. $PFE Shares Sold by Stratos Wealth Partners LTD. - MarketBeat
Capricorn Fund Managers Ltd Invests $4.12 Million in Pfizer Inc. $PFE - MarketBeat
Comirnaty Vaccine: Pfizer-BioNTech COVID-19 Shot - AD HOC NEWS
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements - Yahoo Finance
Raab & Moskowitz Asset Management LLC Sells 39,910 Shares of Pfizer Inc. $PFE - MarketBeat
SteelPeak Wealth LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
PFE Stock Quote Price and Forecast - CNN
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer - Insider Monkey
Pfizer Inc. (PFE) latest press releases and corporate news - Yahoo Finance Singapore
How Pfizer’s Lyme Vaccine Trial Results Could Shape Pipeline Renewal for Pfizer (PFE) Investors - simplywall.st
Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change - Yahoo Finance
Pfizer Loses Bid to Dismiss Disability Bias Lawsuit - National Today
Pfizer Fails to Escape Warehouse Worker’s Disability Bias Suit - Bloomberg Law News
Ever Wonder How Medicines Get Their Names? - Pfizer
38,600 Shares in Pfizer Inc. $PFE Acquired by Genesis Financial Group LLC - MarketBeat
Pfizer Inc. $PFE Stock Position Reduced by First Pacific Financial - MarketBeat
Aberdeen Group plc Sells 664,801 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight - Yahoo Finance
Pfizer RSV vaccine offered to 3M more in England (PFE:NYSE) - Seeking Alpha
Pfizer Site Closure Tests Cost Cuts And R&D Footprint Against Valuation - simplywall.st
Pfizer price soarsForecast today02-04-2026 - Economies.com
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Pfizer’s RSV Shot to Be Offered to 3 Million More in England - bloomberg.com
Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc. - MarketBeat
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
GSK plc (ADR) Stock: ViiV Healthcare Ownership Restructured as Pfizer Exits, Strengthening GSK's HIV - AD HOC NEWS
Pacer S&P 500 Quality FCF High Dividend ETF's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer and BioNTech halt U.S. COVID-19 vaccine study after recruitment struggles - The Japan Times
Why Pfizer (PFE) Outpaced the Stock Market Today - Yahoo Finance
Leerink maintains Pfizer stock rating after vaccine ruling - investing.com
What's Going On With Pfizer Stock Wednesday?BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) - Benzinga
Pfizer, BioNTech halt US trial of COVID-19 vaccine over low enrollment - Daily Sabah
Pfizer, BioNTech end U.S. COVID vaccine trial over low participation: Reuters - Seeking Alpha
Pfizer (PFE) Wins EU Court Case on Vaccine Contracts - gurufocus.com
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID shots - marketscreener.com
Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - marketscreener.com
Belgian court orders Poland, Romania to accept $2.2B of Pfizer COVID shots - Seeking Alpha
Pfizer Inc. - Britannica
Pfizer and partner BioNTech say they will stop U.S. COVID-19 vaccine study in healthy adults ages 50 to 64 due to slow enrollment - marketscreener.com
Pfizer Wins €1.9 Billion Covid Vaccine Case With Poland, Romania - bloomberg.com
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play - TradingView
Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem - Yahoo Finance
Pfizer (PFE) Competes in Prostate Cancer Treatment Landscape - GuruFocus
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines - Reuters
Will Pfizer’s Lyme disease gamble pay off or set the space back? - Pharma Voice
Belgium court orders Romania to take delivery of 600 mln euros worth of Pfizer Covid vaccines - MarketScreener
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pfizer Inc-Aktie (PFE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.84%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):